Business Context and Reporting Period
Company: Achieve Life Sciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 22, 2018
Reporting Period: Specific event date of January 22, 2018.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, or margins. The document focuses on contractual obligations and corporate governance events.
- Immediate Cash Outflow: $37,500 paid upon execution of the License Amendment.
- Prior Payments: $50,000 previously paid under the original License Agreement.
- Contingent Obligations: Up to $1.7 million in aggregate tied to financing, clinical development, and commercialization milestones under the Amendment.
- Original Agreement Obligations: Up to $3.2 million in aggregate tied to specific milestones under the original agreement.
- Royalties: Low-single digits on net sales and mid-teens percentage on sublicense income upon successful commercialization.
Material Changes
The primary material change is the entry into an amendment to the existing license agreement with the University of Bristol dated July 13, 2016.
- Scope Expansion: The Amendment grants the Company exclusive rights for all human medicinal uses of cytisine across all therapeutic categories derived from the Licensor's research activities.
- Term Extension: The agreement continues until the earlier of July 2036 or the expiration of the last patent claim (patents scheduled to expire February 5, 2036, or August 19, 2036).
- Meeting Date Change: The 2018 Annual Meeting of Stockholders was rescheduled from May 24, 2018, to May 22, 2018.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) regarding the Amendment but does not provide forward-looking financial guidance or specific clinical timelines within the text of the 8-K.
Risks and Contingencies:
- Termination: The agreement may be terminated for convenience by the Company with specified notice, or automatically upon bankruptcy, insolvency, or material breach.
- Financial Contingency: Significant future payments are contingent upon achieving specific financing and development milestones.
- Shareholder Nominations: Strict deadlines apply for shareholder director nominations for the 2018 Annual Meeting (between January 24, 2018, and February 24, 2018).
Investor Verification Checklist
- Verify the total aggregate potential liability ($4.9 million in milestone payments) against the Company's current cash position and financing capabilities.
- Confirm the specific clinical development milestones required to trigger the $1.7 million in payments under the Amendment.
- Review the press release (Exhibit 99.1) for details on the strategic rationale for expanding the cytisine license scope.
- Check the Company's patent portfolio status to ensure alignment with the 2036 expiration dates cited in the agreement.